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Dear Sirs,
The hereditary spastic paraplegias (HSPs) are a genet-
ically heterogeneous group of disorders characterised
by progressive corticospinal tract degeneration and the
development of lower limb spasticity [1, 2]. Autoso-
mal-dominant HSP is the most commonly inherited
form of the disease and in this group, SPG4 mutations
account for *40 % of cases [1]. The SPG4 gene codes
for spastin, a critical neuronal protein that maintains
organelle axonal transport by severing and rearranging
the microtubule network [3, 4]. Dysfunctional mutant
proteins or insufficient quantities of the wild-type
protein inhibit this dynamic shuttling process resulting
in axonal swelling and progressive retrograde degen-
eration that preferentially affects the long corticospinal
axons [3, 4].
There is mounting evidence that the microtubule and
mitochondrial networks are intrinsically linked at the
cellular level [5]. This intriguing association has recently
been highlighted by the clinical observation that autoso-
mal-dominant optic atrophy (DOA)—a classical mito-
chondrial optic neuropathy caused by pathogenic OPA1
mutations—can result in complicated neurological phe-
notypes (DOA?) with features indistinguishable from
HSP [6]. Furthermore, subclinical corticospinal tract
dysfunction also seems to be a prevalent feature among
OPA1 mutation carriers presenting with isolated visual
failure, suggesting a wider disease spectrum than origi-
nally considered [7]. Interestingly, these overlapping
genotype-phenotype manifestations have been reported
previously in families with a rarer, autosomal-recessive
form of HSP caused by pathogenic SPG7 mutations, in
which bilateral optic atrophy was a prominent feature
segregating with spastic paraplegia [8–10]. Given the
emerging disease mechanisms linking corticospinal tract
dysfunction with optic nerve degeneration, the aim of this
study was to determine the neurological and ophthalmo-
logical manifestations of SPG4-related HSP, looking
specifically for evidence of clinical or subclinical optic
neuropathy among affected patients. The overall neuro-
logical disability, including cognitive function, was also
evaluated to provide a comprehensive assessment of the
burden of disease in this group of patients.
A comprehensive neurological (GP, RH, PFC) and
ophthalmological (PYWM) assessment (Supplementary
Method) was carried out on ten white patients from the
North of England harbouring confirmed pathogenic
SPG4 mutations (Table 1). A broad spectrum of
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neurological disability was observed among affected
patients with scores ranging from one to nine on the
modified EDSS scale (Table 2). Importantly, four
patients had abnormal MOCA scores of less than 26
points. Seven patients performed poorly on the memory
component of the MOCA test protocol and one patient
had abnormal visuospatial/executive performance. The
association between SPG4 mutations and progressive
cognitive decline remains controversial [11–13] and our
study of a well-characterised patient cohort provides
further evidence favouring a true causal link. Two of the
patients with abnormal MOCA scores were younger than
the age of 30 years, clearly highlighting the need for
clinical vigilance to detect early signs of cognitive
impairment and to provide adequate level of support,
especially to carers.
Except for one patient who had bilateral nuclear
sclerotic cataracts, all patients had best-corrected visual
acuities of 20/20 bilaterally (Table 1). The ophthalmolog-
ical examination was normal with full colour discrimina-
tion and no detectable optic disc or retinal abnormalities.
Visual fields, RNFL thickness measurements and visual
electrophysiology were within the normal range for the
entire HSP patient cohort. Three patients had abnormal eye
movements with horizontal square wave jerks and saccadic
smooth pursuits. No significant ptosis or limitation of eye
movements was noted on orthoptic assessment. Based on
our comprehensive clinical and electrophysiological eval-
uation, visual loss secondary to optic nerve or retinal
degeneration is unlikely to be a major phenotypic mani-
festation of SPG4-related disease. Affected patients and at-
risk family members can therefore be reassured that unlike
other genetically-determined forms of HSP [6–10], SPG4
mutations are not associated with the development of sig-
nificant ophthalmological complications, in particular
visual failure.
Table 1 Molecular genetic and ophthalmological features of the SPG4 patient cohort
Patient Sex Age
(years)
SPG4 mutation BCVA
RE-LE
Optic discs/OCT
measurements
Eye
movements
Visual
electrophysiology
Exon cDNA change/
consequence
1 F 31 5 c.743C[G/p.S245X 20/20-20/20 Normal/no RNFL
thinning
Normal Normal
2 M 53 5 c.743C[G/p.S245X 20/20-20/20 Normal/no RNFL
thinning
Horizontal SWJ/
saccadic pursuit
Normal
3 F 50 6 c.937delG/p.D313fsX1 20/20-20/20 Normal/no RNFL
thinning
Normal Normal
4 F 55 4–17 del exon 4-17/large-scale
deletion
20/20-20/20 Normal/no RNFL
thinning
Normal Normal
5 F 29 10 c.1253_1255delAAG/
p.E418fsX198
20/20-20/20 Normal/no RNFL
thinning
Horizontal SWJ/
saccadic pursuit
Normal
6 F 25 11 c.1442_1443insA/
p.V482fsX5
20/20-20/20 Normal/no RNFL
thinning
Normal Normal
7 F 55 11 c.1442_1443insA/
p.V482fsX5
20/20-20/20 Normal/no RNFL
thinning
Horizontal SWJ/
saccadic pursuit
Normal
8 F 49 11 c.1414G[A/p.V472I 20/20-20/20 Normal/no RNFL
thinning
Normal Normal
9 F 72 11 c.1384A[G/p.K462E 20/60-20/30 Normal/no RNFL
thinning
Normal Normal
10 M 65 11 c.1081C[A; c.1082T[A/
p.L361N
20/20-20/20 Normal/no RNFL
thinning
Normal Normal
BCVA best-corrected visual acuities, cDNA complementary DNA, LE left eye, OCT optical coherence tomography, RE right eye, RNFL retinal
nerve fibre layer, SWJ square wave jerks
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